|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Englinger B, Mair M, Miklos W, Pirker C,
Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller
S, et al: Loss of CUL4A expression is underlying cisplatin
hypersensitivity in colorectal carcinoma cells with acquired
trabectedin resistance. Br J Cancer. 116:489–500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen MH, Gootenberg J, Keegan P and
Pazdur R: FDA drug approval summary: Bevacizumab plus FOLFOX4 as
second-line treatment of colorectal cancer. Oncologist. 12:356–361.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arnold D, Prager GW, Quintela A, Stein A,
Moreno Vera S, Mounedji N and Taieb J: Beyond second-line therapy
in patients with metastatic colorectal cancer: A systematic review.
Ann Oncol. 29:835–856. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stintzing S: Management of colorectal
cancer. F1000Prime Rep. 6:1082014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ellman MB, Yan D, Ahmadinia K, Chen D, An
HS and Im HJ: Fibroblast growth factor control of cartilage
homeostasis. J Cell Biochem. 114:735–742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ornitz DM and Itoh N: The Fibroblast
Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol.
4:215–266. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dieci MV, Arnedos M, Andre F and Soria JC:
Fibroblast growth factor receptor inhibitors as a cancer treatment:
From a biologic rationale to medical perspectives. Cancer Discov.
3:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sato T, Oshima T, Yoshihara K, Yamamoto N,
Yamada R, Nagano Y, Fujii S, Kunisaki C, Shiozawa M, Akaike M, et
al: Overexpression of the fibroblast growth factor receptor-1 gene
correlates with liver metastasis in colorectal cancer. Oncol Rep.
21:211–216. 2009.PubMed/NCBI
|
|
12
|
Ornitz DM, Xu J, Colvin JS, McEwen DG,
MacArthur CA, Coulier F, Gao G and Goldfarb M: Receptor specificity
of the fibroblast growth factor family. J Biol Chem.
271:15292–15297. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J and Slack JM: XFGF-9: A new
fibroblast growth factor from Xenopus embryos. Dev Dyn.
206:427–436. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohgino K, Soejima K, Yasuda H, Hayashi Y,
Hamamoto J, Naoki K, Arai D, Ishioka K, Sato T, Terai H, et al:
Expression of fibroblast growth factor 9 is associated with poor
prognosis in patients with resected non-small cell lung cancer.
Lung Cancer. 83:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: miR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fillmore CM, Gupta PB, Rudnick JA,
Caballero S, Keller PJ, Lander ES and Kuperwasser C: Estrogen
expands breast cancer stem-like cells through paracrine FGF/Tbx3
signaling. Proc Natl Acad Sci USA. 107:21737–21742. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Y, Jin C, Hamana T, Liu J, Wang C,
An L, McKeehan WL and Wang F: Overexpression of FGF9 in prostate
epithelial cells augments reactive stroma formation and promotes
prostate cancer progression. Int J Biol Sci. 11:948–960. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen TM, Shih YH, Tseng JT, Lai MC, Wu CH,
Li YH, Tsai SJ and Sun HS: Overexpression of FGF9 in colon cancer
cells is mediated by hypoxia-induced translational activation.
Nucleic Acids Res. 42:2932–2944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arwert EN, Hoste E and Watt FM: Epithelial
stem cells, wound healing and cancer. Nat Rev Cancer. 12:170–180.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sierra J, Yoshida T, Joazeiro CA and Jones
KA: The APC tumor suppressor counteracts beta-catenin activation
and H3K4 methylation at Wnt target genes. Genes Dev. 20:586–600.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang C, Yu M, Xie X, Huang G, Peng Y, Ren
D, Lin M, Liu B, Liu M, Wang W and Kuang M: miR-217 targeting DKK1
promotes cancer stem cell properties via activation of the Wnt
signaling pathway in hepatocellular carcinoma. Oncol Rep.
38:2351–2359. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen B, Zhang D, Kuai J, Cheng M, Fang X
and Li G: Upregulation of miR-199a/b contributes to cisplatin
resistance via Wnt/β-catenin-ABCG2 signaling pathway in
ALDHA1+colorectal cancer stem cells. Tumour Biol.
39:10104283177151552017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chikazawa N, Tanaka H, Tasaka T, Nakamura
M, Tanaka M, Onishi H and Katano M: Inhibition of Wnt signaling
pathway decreases chemotherapy-resistant side-population colon
cancer cells. Anticancer Res. 30:2041–2048. 2010.PubMed/NCBI
|
|
28
|
Schneikert J and Behrens J: The canonical
Wnt signalling pathway and its APC partner in colon cancer
development. Gut. 56:417–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leushacke M, Sporle R, Bernemann C,
Brouwer-Lehmitz A, Fritzmann J, Theis M, Buchholz F, Herrmann BG
and Morkel M: An RNA interference phenotypic screen identifies a
role for FGF signals in colon cancer progression. PLoS One.
6:e233812011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizukami T, Togashi Y, Naruki S, Banno E,
Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita
Y, et al: Significance of FGF9 gene in resistance to anti-EGFR
therapies targeting colorectal cancer: A subset of colorectal
cancer patients with FGF9 upregulation may be resistant to
anti-EGFR therapies. Mol Carcinog. 56:106–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsiao KY, Lin YC, Gupta SK, Chang N, Yen
L, Sun HS and Tsai SJ: Noncoding effects of circular RNA CCDC66
promote colon cancer growth and metastasis. Cancer Res.
77:2339–2350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng Z, Kang HY, Lee S, Kang SW, Goo B
and Cho SB: Up-regulation of fibroblast growth factor (FGF) 9
expression and FGF-WNT/β-catenin signaling in laser-induced wound
healing. Wound Repair Regen. 22:660–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
